Skip navigation

Prostate Health Diagnostic Panel

The Next Evolution in Prostate Health Diagnostics

Benign Prostatic Hyperplasia (BPH) is a common condition that increases with age and generates a false positive signal for Prostate Cancer when utilizing Prostate Specific Antigen (PSA) as a diagnostic tool. It presents with symptoms very similar to those of Prostate Cancer; however, BPH is non-malignant.  Collectively, these symptoms known as LUTS (lower urinary tract symptoms) make the two conditions nearly indistinguishable on presentation.

BPH is a dominant condition in men at risk for Prostate Cancer that often leads to over recommendation of Prostate biopsies.

Being able to make the distinction between BPH and Prostate Cancer early in the diagnostic pipeline is a much needed evolution in Prostate Health diagnostics.

 

Current Prostate Health Diagnostic Landscape

There is a Lack of Specificity Without Invasive Biopsy

The available tools for diagnosing Prostate Cancer are limited in usefulness or are invasive with risk of complications revealing an unmet need for better Prostate Health diagnostics.

Current Standard of Care for diagnosis includes:

The Unmet Need in Prostate Health Diagnostics

There is a clear and defined unmet need for the development of molecular diagnostics that stratify men with Benign Prostatic Hyperplasia (BPH) from those that have Prostate Cancer to prevent unnecessary Prostate biopsies.

The BPGbio Prostate Health Diagnostic Panel

BPGbio introduces the next evolution in Prostate Health Diagnostic Panels identified and developed, with a biomarker panel validated, using our Interrogative Biology® platform.

Advantages include:

  • A Non-Invasive Serum Blood Test – Novel mechanism to distinguish between BPH and Prostate Cancer
  • A Non-PSA Based Test – Reduces the need for prostate biopsies
  • Effectively Rules Out Aggressive Prostate Cancers

Benefits to Prostate Diagnosis & Care:

Avoid costly and invasive biopsies and reduce anxiety related to elevated PSA levels.

Use of the BPGbio panel may be better for monitoring patients after a negative biopsy over competing products.

Care can be continued under patient PCP, avoiding costly procedures associated with urologists.

 

The BPGbio Prostate Health Diagnostic Panel Competitive Advantage

The BPGbio Prostate Health Diagnostic Panel promises demonstrated clinical utility in stratification of Benign Prostate Cancer Hyperplasia (BPH) from Prostate Cancer; thus, leading to the reduction of false positives and, as a result, less need for prostate biopsies.

The BPGbio Prostate Health Diagnostic Panel addresses this unmet need with exceptionally competitive demonstrated accuracy using serum-based testing (non-PSA based test).